+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Pediatrics Pneumococcal Therapeutics Market by Product, Age Group, Disease Type, Mode of Administration, Therapeutic Applications, End-User - Global Forecast to 2030- Product Image
Pediatrics Pneumococcal Therapeutics Market by Product, Age Group, Disease Type, Mode of Administration, Therapeutic Applications, End-User - Global Forecast to 2030- Product Image
Sale

Pediatrics Pneumococcal Therapeutics Market by Product, Age Group, Disease Type, Mode of Administration, Therapeutic Applications, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6055447
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Pediatrics Pneumococcal Therapeutics Market grew from USD 17.15 billion in 2024 to USD 18.51 billion in 2025. It is expected to continue growing at a CAGR of 8.14%, reaching USD 27.43 billion by 2030.

Setting the Stage for Pediatric Pneumococcal Therapeutics Excellence

The pediatric pneumococcal therapeutics field stands at a pivotal point where scientific breakthroughs and clinical imperatives converge to redefine treatment paradigms. Increasing rates of antibiotic resistance among Streptococcus pneumoniae strains underscore the urgency for innovative vaccines and targeted drug therapies. Simultaneously, healthcare stakeholders demand solutions that balance efficacy, safety, and cost-effectiveness for vulnerable infant and toddler populations.

Against this backdrop, this executive summary illuminates the critical themes driving the industry forward. We examine the evolving competitive landscape shaped by next-generation conjugate vaccines, explore policy shifts that influence access and affordability, and analyze the nuanced behaviors of end-users in clinical, hospital, and homecare settings. By distilling complex data into strategic insights, this introduction sets the stage for understanding how science, regulation, and market forces coalesce to shape the future of pediatric pneumococcal care.

Unveiling the Transformative Forces Shaping the Pediatric Pneumococcal Arena

Recent years have witnessed a profound transformation in how pneumococcal diseases are prevented and treated among children. Advances in conjugate vaccine technology now enable broader serotype coverage while reducing reactogenicity, pushing manufacturers to accelerate their pipelines. Telemedicine platforms and digital health monitoring tools have emerged as crucial adjuncts for tracking vaccine adherence and adverse events, thereby enhancing real-world evidence generation.

On the policy front, global health organizations have rebalanced their priorities toward equitable vaccine distribution, prompting tiered pricing models and expanded public-private partnerships. Meanwhile, clinicians are increasingly tailoring therapeutic regimens based on regional serotype prevalence and individual risk factors, reflecting a shift from one-size-fits-all protocols to precision immunization strategies. This evolving interplay between innovation, regulatory adaptation, and clinical customization encapsulates the transformative forces reshaping pediatric pneumococcal care today.

Assessing the Ripples of New US Tariffs on Pneumococcal Treatment Access

The introduction of new United States tariffs in 2025 has introduced a complex layer of economic pressure across the supply chain for pneumococcal drugs and vaccines. Import duties on key raw materials, including polysaccharide antigens and specialized adjuvants, have led manufacturers to reassess production locations and supplier partnerships. Several companies have proactively relocated manufacturing lines to domestic facilities to mitigate cost inflation, yet these strategic moves require significant capital investment and regulatory revalidation.

Providers and payers now face higher acquisition costs for both drug therapies and conjugate vaccines, prompting budgetary adjustments within pediatric immunization programs. Some regional healthcare networks have responded by optimizing inventory management and negotiating volume-based discounts, while others have pivoted toward biosimilar products where clinically appropriate. The net result of these tariffs is a recalibration of pricing dynamics that will reverberate throughout the pediatric pneumococcal market, compelling stakeholders to evolve their procurement and distribution strategies.

Decoding Market Segments to Drive Pediatric Pneumococcal Strategies

Breaking down the market by product reveals a clear bifurcation between therapeutic drugs and preventive vaccines, with the latter subdividing into advanced conjugate and traditional polysaccharide formulations that cater to differing immunization needs. Examining age group dynamics highlights that interventions for infants demand rigorous safety profiles and minimal dosing schedules, while toddler programs emphasize booster strategies to sustain immunity through early childhood.

Differentiating by disease type underscores distinct clinical pathways: antibacterial regimens tailored to bacterial pneumonia contrast with adjunctive therapies for mycoplasma pneumonia, and supportive measures for viral pneumonia. The mode of administration dimension further differentiates offerings, as intramuscular injections remain standard for vaccines, whereas oral and intranasal routes gain traction for ease of use in community settings. Therapeutic applications for invasive conditions like bacteremia and meningitis require high-potency formulations, whereas non-invasive indications such as otitis media and sinusitis pursue broader coverage with lower reactogenicity profiles. Finally, the end-user landscape spans clinics, hospitals, and homecare environments, each demanding unique delivery, storage, and patient education protocols. Together, these segmentation lenses provide a granular view of unmet needs and growth opportunities across the pediatric pneumococcal therapeutics spectrum.

Regional Dynamics Steering Pediatric Pneumococcal Market Growth

Across the Americas, robust immunization campaigns and public funding initiatives continue to accelerate vaccine uptake, yet fragmented healthcare delivery systems create pockets of under-served rural populations. Innovative outreach models and mobile clinics are gaining traction to bridge these access gaps. Europe, Middle East & Africa encompasses a diverse array of health infrastructures, from advanced regulatory frameworks in Western Europe to resource-constrained settings in parts of Africa. This divergence necessitates differentiated pricing, localized manufacturing partnerships, and region-specific education efforts to ensure broad protective coverage.

The Asia-Pacific region presents both rapid urbanization and varying public health priorities. High-population nations are investing heavily in domestic vaccine production capabilities to secure supply chain resilience, while smaller markets lean on international collaborations to fast-track licensure. Cultural attitudes toward immunization and disease prevention shape demand patterns, prompting stakeholders to tailor communication strategies that resonate with caregivers’ values. By understanding these regional dynamics, industry players can craft nuanced market entry plans and optimize resource allocation.

Profiling the Leaders Advancing Pneumococcal Therapeutic Frontiers

A handful of global pharmaceutical leaders dominate the pediatric pneumococcal landscape through extensive vaccine portfolios and robust R&D pipelines. Many have formed strategic alliances with biotech innovators to accelerate next-generation conjugate constructs, leveraging novel carrier proteins and adjuvant systems. Emerging players from Asia-Pacific are gaining ground by capitalizing on lower-cost manufacturing footprints and aggressive regional licensing strategies.

Technology firms specializing in digital immunization tracking are also carving out roles as key enablers, collaborating with manufacturers and healthcare providers to integrate data analytics into vaccine rollout programs. Contract research organizations contribute by offering specialized clinical trial expertise, helping to validate new formulations across diverse pediatric cohorts. Collectively, this network of incumbents, challengers, and enablers defines the competitive ecosystem, driving relentless pursuit of enhanced efficacy, safety, and access for pediatric patients. Understanding each company’s unique strengths and strategic priorities is essential for stakeholders seeking impactful partnerships and licensing opportunities.

Strategic Moves to Capitalize on Emerging Pediatric Pneumococcal Trends

To capitalize on the evolving pediatric pneumococcal landscape, industry leaders should prioritize diversification of their development portfolios, balancing proprietary conjugate vaccines with novel drug therapies and biosimilar candidates. Strengthening local manufacturing capabilities in tariff-affected regions will enhance supply chain agility and reduce exposure to import duties. Partnerships with digital health innovators can streamline immunization adherence tracking and real-world evidence generation, elevating product value propositions.

Moreover, engaging directly with healthcare systems through outcome-based contracts can foster shared risk models and reinforce the case for premium products. Tailoring communication campaigns to address regional cultural norms and caregiver concerns will improve uptake in under-served markets. Finally, investing in next-phase clinical studies that explore alternative administration routes and combination therapies can open new avenues for growth. By adopting a holistic approach that integrates product innovation, supply chain resilience, and stakeholder collaboration, companies can secure sustainable leadership in pediatric pneumococcal care.

Rigorous Framework Underpinning the Pediatric Pneumococcal Study

This analysis synthesized insights from primary interviews with key opinion leaders, including pediatric infectious disease specialists and immunization policy advisors. We conducted secondary research across peer-reviewed journals, regulatory filings, and public health databases to capture the latest efficacy and safety data for pneumococcal interventions. Competitive intelligence was gleaned through analysis of patent landscapes, clinical trial registries, and corporate press releases, ensuring a comprehensive view of the innovation pipeline.

We applied a multi-dimensional segmentation framework to assess unmet needs across product types, age cohorts, disease indications, administration modes, therapeutic applications, and end-user settings. Regional market dynamics were evaluated through examination of healthcare infrastructure indices and country-level immunization coverage statistics. Finally, scenario analyses explored the implications of regulatory changes, tariff adjustments, and technological advancements. Throughout the methodology, triangulation and rigorous cross-validation guaranteed the reliability and insights presented in this report.

Synthesis of Key Insights Shaping Future Pneumococcal Strategies

Bringing together the key findings, it becomes clear that the pediatric pneumococcal therapeutics market is entering a phase of strategic transformation fueled by scientific innovation, policy reshaping, and economic recalibration. The tariff-induced cost pressures underline the critical need for supply chain optimization and regional manufacturing solutions. Advanced conjugate vaccines and novel drug candidates are poised to address persistent gaps in serotype coverage and antibiotic resistance, while digital health partnerships offer enhanced patient engagement and data collection capabilities.

Segmentation insights reveal targeted opportunities across product modalities, age groups, disease categories, and end-user channels. Regional analyses highlight the varied pace of adoption and underscore the importance of customized entry strategies. Competitive profiling emphasizes the value of collaborative ecosystems that merge big pharma’s scale with biotech agility and digital health prowess. These cohesive insights equip stakeholders with a roadmap for informed decision-making and strategic investment as the industry strives to improve pediatric health outcomes globally.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Product
    • Drug
    • Vaccine
      • Conjugate Vaccine
      • Polysaccharide Vaccine
  • Age Group
    • Infants
    • Toddlers
  • Disease Type
    • Bacterial Pneumonia
    • Mycoplasma Pneumonia
    • Viral Pneumonia
  • Mode of Administration
    • Intramuscular
    • Intranasal
    • Intravenous
    • Oral
  • Therapeutic Applications
    • Invasive Pneumococcal Diseases
      • Bacteremia
      • Meningitis
    • Non-Invasive Pneumococcal Diseases
      • Otitis Media
      • Sinusitis
  • End-User
    • Clinics
    • Homecare Settings
    • Hospitals
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Biocon Limited
  • CanSino Biologics Inc.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche AG
  • Lupin Limited
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd
  • Sinovac Biotech Ltd.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
3.1. Evolving Role and Historical Progression of the Pediatrics Pneumococcal Therapeutics Market
3.2. Quantitative Drivers and Strategic Competitive Dynamics in Pediatrics Pneumococcal Therapeutics
3.3. Lifecycle and Intellectual Property Strategies Tailored to Market Phases and Competitive Pressures
3.4. Strategic Growth Options, Emerging Trends, and Market Evolution Outlook
4. Market Overview
4.1. Introduction
4.1.1. Pediatrics Pneumococcal Therapeutics Market Fundamentals and Growth Catalysts
4.1.2. Regional Insights and Trade Dynamics Shaping Market Penetration and Acceptance
4.1.3. Recent Innovations, Collaborations, and Strategic Movements Fueling Market Evolution
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Increasing adoption of conjugate pneumococcal vaccines in pediatric immunization programs worldwide
5.1.1. Understanding the Rising Adoption of Conjugate Pneumococcal Vaccines in Pediatric Care
5.1.2. Market Transformation and Business Opportunities Driven by Increased Vaccine Adoption
5.1.3. Future Outlook and Strategic Recommendations for Sustained Growth in Pediatric Pneumococcal Vaccination
5.2. Emerging multi-valent pneumococcal vaccine candidates showing enhanced protection in children
5.2.1. Defining multi-valent pneumococcal vaccines and their role in pediatric health protection
5.2.2. How multi-valent vaccines are driving innovation and expanding market opportunities in pediatrics
5.2.3. Future outlook and strategic considerations for multi-valent pneumococcal vaccines in pediatric care
5.3. Growing emphasis on herd immunity through expanded pediatric pneumococcal vaccination coverage
5.4. Innovations in pneumococcal vaccine delivery methods improving compliance among pediatric patients
5.5. Rising prevalence of antibiotic-resistant Streptococcus pneumoniae strains influencing therapeutic strategies in pediatrics
5.6. Investment in pediatric pneumococcal vaccine research driven by unmet medical needs in low-income countries
5.7. Integration of pneumococcal vaccination with routine childhood immunization schedules to improve uptake
5.8. Advancements in diagnostics facilitating early detection and targeted treatment of pneumococcal infections in children
5.9. Impact of global health initiatives and funding on increasing access to pneumococcal therapeutics for children
5.10. Development of combination vaccines addressing multiple childhood pathogens including pneumococcus
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.1.1. High Barriers Limit New Entrants in Pediatrics Pneumococcal Therapeutics Market
6.1.2. Moderate Substitution Threat Amidst Evolving Vaccine Technologies
6.1.3. Specialized Inputs Elevate Supplier Influence on Pricing and Supply
6.1.4. Concentrated Buyers Drive Competitive Pricing and Quality Demands
6.1.5. Intense Rivalry Spurs Innovation and Competitive Differentiation in Vaccine Market
6.2. PESTLE Analysis
6.2.1. Political momentum in public immunization programs driving vaccine demand
6.2.2. Economic dynamics shaping vaccine affordability and government healthcare investment
6.2.3. Demographic growth and shifting vaccine acceptance fueling market expansion
6.2.4. Innovative vaccine technologies and digital infrastructure enhancing efficacy and distribution
6.2.5. Regulatory rigor and intellectual property laws shaping innovation and compliance
6.2.6. Sustainability pressures and climate resilience shaping operational and reputational strategies
7. Cumulative Impact of United States Tariffs 2025
7.1. Major United States Tariffs Impacting Pediatrics Pneumococcal Therapeutics from 2023 to 2025
7.2. Historical Background and Economic Rationale of US Tariff Policies from 2018 to 2025
7.3. Direct Contribution of US Tariffs to Inflationary Pressures in the Global Economy
7.4. Impact of Reciprocal Tariffs and Emerging Trade Wars Across Key Regions
7.5. Economic and Political Consequences of US Tariffs on Major Trading Partners
7.6. Long-Term Structural Changes in the US Economy Driven by Tariff Policies
7.7. Strategies and Policy Responses to Alleviate Tariff-Driven Economic Challenges
8. Pediatrics Pneumococcal Therapeutics Market, by Product
8.1. Introduction
8.2. Drug
8.3. Vaccine
8.3.1. Conjugate Vaccine
8.3.2. Polysaccharide Vaccine
9. Pediatrics Pneumococcal Therapeutics Market, by Age Group
9.1. Introduction
9.2. Infants
9.3. Toddlers
10. Pediatrics Pneumococcal Therapeutics Market, by Disease Type
10.1. Introduction
10.2. Bacterial Pneumonia
10.3. Mycoplasma Pneumonia
10.4. Viral Pneumonia
11. Pediatrics Pneumococcal Therapeutics Market, by Mode of Administration
11.1. Introduction
11.2. Intramuscular
11.3. Intranasal
11.4. Intravenous
11.5. Oral
12. Pediatrics Pneumococcal Therapeutics Market, by Therapeutic Applications
12.1. Introduction
12.2. Invasive Pneumococcal Diseases
12.2.1. Bacteremia
12.2.2. Meningitis
12.3. Non-Invasive Pneumococcal Diseases
12.3.1. Otitis Media
12.3.2. Sinusitis
13. Pediatrics Pneumococcal Therapeutics Market, by End-User
13.1. Introduction
13.2. Clinics
13.3. Homecare Settings
13.4. Hospitals
14. Americas Pediatrics Pneumococcal Therapeutics Market
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. Argentina
15. Europe, Middle East & Africa Pediatrics Pneumococcal Therapeutics Market
15.1. Introduction
15.2. United Kingdom
15.3. Germany
15.4. France
15.5. Russia
15.6. Italy
15.7. Spain
15.8. United Arab Emirates
15.9. Saudi Arabia
15.10. South Africa
15.11. Denmark
15.12. Netherlands
15.13. Qatar
15.14. Finland
15.15. Sweden
15.16. Nigeria
15.17. Egypt
15.18. Turkey
15.19. Israel
15.20. Norway
15.21. Poland
15.22. Switzerland
16. Asia-Pacific Pediatrics Pneumococcal Therapeutics Market
16.1. Introduction
16.2. China
16.3. India
16.4. Japan
16.5. Australia
16.6. South Korea
16.7. Indonesia
16.8. Thailand
16.9. Philippines
16.10. Malaysia
16.11. Singapore
16.12. Vietnam
16.13. Taiwan
17. Competitive Landscape
17.1. Market Share Analysis, 2024
17.2. FPNV Positioning Matrix, 2024
17.3. Competitive Analysis
17.3.1. AbbVie Inc.
17.3.1.1. AbbVie's Strategic Market Entry, Expansion, and Current Competitive Positioning
17.3.1.2. Deep Dive into AbbVie's Flagship Pediatric Pneumococcal Vaccines and Unique Market Differentiators
17.3.1.3. Navigating Risks and Fortifying AbbVie's Pediatric Pneumococcal Therapeutics Portfolio for Future Success
17.3.2. Astellas Pharma Inc.
17.3.2.1. Astellas Pharma's Established Market Presence and Strategic Positioning in Pediatric Therapeutics
17.3.2.2. Flagship Pneumococcal Therapeutics Aligning Innovation with Pediatric Patient Needs
17.3.2.3. Navigating Challenges and Leveraging Innovation for Long-Term Growth in Pediatric Therapeutics
17.3.3. Aurobindo Pharma Limited
17.3.3.1. Aurobindo Pharma’s Current Market Role and Strategic Footprint in Pediatric Pneumococcal Therapeutics
17.3.3.2. Flagship Pediatric Pneumococcal Therapeutics and Their Market Differentiators at Aurobindo Pharma
17.3.3.3. Assessing Risks and Strategic Growth Opportunities for Aurobindo Pharma in Pediatric Pneumococcal Therapeutics
17.3.4. Baxter International Inc.
17.3.5. Biocon Limited
17.3.6. CanSino Biologics Inc.
17.3.7. Daiichi Sankyo Company, Limited
17.3.8. Dr. Reddy's Laboratories Ltd.
17.3.9. GlaxoSmithKline plc
17.3.10. Hoffmann-La Roche AG
17.3.11. Lupin Limited
17.3.12. Merck & Co., Inc
17.3.13. Novartis AG
17.3.14. Pfizer Inc.
17.3.15. Sanofi S.A.
17.3.16. Serum Institute of India Pvt. Ltd
17.3.17. Sinovac Biotech Ltd.
18. ResearchAI
19. ResearchStatistics
20. ResearchContacts
21. ResearchArticles
22. Appendix
List of Figures
FIGURE 1. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET MULTI-CURRENCY
FIGURE 2. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET MULTI-LANGUAGE
FIGURE 3. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
FIGURE 8. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2030 (%)
FIGURE 10. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 18. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 22. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. ASIA-PACIFIC PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 28. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DRUG, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY CONJUGATE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY POLYSACCHARIDE VACCINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY BACTERIAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MYCOPLASMA PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VIRAL PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY BACTEREMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY OTITIS MEDIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY SINUSITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 39. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 40. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 41. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 48. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 49. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 50. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 58. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 59. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 60. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 61. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 62. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 63. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 64. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 65. CANADA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 67. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 68. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 69. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 71. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 72. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 73. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 74. MEXICO PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 109. UNITED KINGDOM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 110. UNITED KINGDOM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 111. UNITED KINGDOM PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 113. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 114. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 115. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 116. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 118. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 119. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 120. GERMANY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 122. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 123. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 124. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 125. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 126. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 127. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 128. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 129. FRANCE PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 133. RUSSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 134. RUSSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 135. RUSSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 136. RUSSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 137. RUSSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 138. RUSSIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 140. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 141. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 142. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 143. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 145. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 146. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 147. ITALY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. SPAIN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 149. SPAIN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 150. SPAIN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 151. SPAIN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 152. SPAIN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. SPAIN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 154. SPAIN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 155. SPAIN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 156. SPAIN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 157. UNITED ARAB EMIRATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 158. UNITED ARAB EMIRATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 159. UNITED ARAB EMIRATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 160. UNITED ARAB EMIRATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 161. UNITED ARAB EMIRATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 162. UNITED ARAB EMIRATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 163. UNITED ARAB EMIRATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 164. UNITED ARAB EMIRATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 165. UNITED ARAB EMIRATES PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 166. SAUDI ARABIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 167. SAUDI ARABIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 168. SAUDI ARABIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 169. SAUDI ARABIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 170. SAUDI ARABIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 171. SAUDI ARABIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 172. SAUDI ARABIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 173. SAUDI ARABIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 174. SAUDI ARABIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 175. SOUTH AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 176. SOUTH AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 177. SOUTH AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 178. SOUTH AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 179. SOUTH AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 180. SOUTH AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 181. SOUTH AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 182. SOUTH AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 183. SOUTH AFRICA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 185. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 186. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 187. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 188. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 189. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 190. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 191. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 192. DENMARK PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 193. NETHERLANDS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 194. NETHERLANDS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 195. NETHERLANDS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 196. NETHERLANDS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 197. NETHERLANDS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. NETHERLANDS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 199. NETHERLANDS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 200. NETHERLANDS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 201. NETHERLANDS PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 202. QATAR PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 203. QATAR PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 204. QATAR PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 205. QATAR PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 206. QATAR PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. QATAR PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 208. QATAR PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 209. QATAR PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 210. QATAR PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 211. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 212. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 213. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 214. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 215. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 216. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 217. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 218. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 219. FINLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 220. SWEDEN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 221. SWEDEN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 222. SWEDEN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 223. SWEDEN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 224. SWEDEN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 225. SWEDEN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 226. SWEDEN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 227. SWEDEN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 228. SWEDEN PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. NIGERIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 230. NIGERIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 231. NIGERIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 232. NIGERIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 233. NIGERIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 234. NIGERIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 235. NIGERIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 236. NIGERIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 237. NIGERIA PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 238. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 239. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 240. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 241. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 242. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 244. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 245. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 246. EGYPT PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 247. TURKEY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 248. TURKEY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 249. TURKEY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 250. TURKEY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 251. TURKEY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 252. TURKEY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 253. TURKEY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 254. TURKEY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 255. TURKEY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 257. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 258. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 259. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 260. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 261. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 262. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 263. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 264. ISRAEL PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 265. NORWAY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 266. NORWAY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 267. NORWAY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 268. NORWAY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 269. NORWAY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 270. NORWAY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 271. NORWAY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 272. NORWAY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 273. NORWAY PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 274. POLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
TABLE 275. POLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY VACCINE, 2018-2030 (USD MILLION)
TABLE 276. POLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 277. POLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 278. POLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 279. POLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATIONS, 2018-2030 (USD MILLION)
TABLE 280. POLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 281. POLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY NON-INVASIVE PNEUMOCOCCAL DISEASES, 2018-2030 (USD MILLION)
TABLE 282. POLAND PEDIATRICS PNEUMOCOCCAL THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 283. SWITZERLAND PEDIATRICS PNEUMOC

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Pediatrics Pneumococcal Therapeutics market report include:
  • AbbVie Inc.
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Biocon Limited
  • CanSino Biologics Inc.
  • Daiichi Sankyo Company, Limited
  • Dr. Reddy's Laboratories Ltd.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche AG
  • Lupin Limited
  • Merck & Co., Inc
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Serum Institute of India Pvt. Ltd
  • Sinovac Biotech Ltd.

Table Information

Report AttributeDetails
No. of Pages187
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 18.51 Billion
Forecasted Market Value ( USD ) by 2030 $ 27.43 Billion
Compound Annual Growth Rate8.1%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Pediatric Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Pediatric Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 150 Pages
  • Global
From
Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Pediatric Vaccines Market Size, Share & Trends Analysis Report By Type (Monovalent, Multivalent), By Technology (Live Attenuated Vaccines), By Application (Cancer), By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
Pediatric Vaccines Market by Vaccine Type, by Technology, by Indication, by Distribution Channel, and by Region - Product Image

Pediatric Vaccines Market by Vaccine Type, by Technology, by Indication, by Distribution Channel, and by Region

  • Report
  • 200 Pages
  • Global
From
Pediatric Vaccines Market by Vaccine Type, Disease, Distribution Channel, End User, Technology, Age Group - Global Forecast to 2030 - Product Image

Pediatric Vaccines Market by Vaccine Type, Disease, Distribution Channel, End User, Technology, Age Group - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Pediatric Vaccine Market Opportunities and Strategies to 2033 - Product Image

Pediatric Vaccine Market Opportunities and Strategies to 2033

  • Report
  • 286 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.